Advancing Next-Generation Antibody Therapeutics
Bright Biologics is developing next-generation antibody therapeutics using proprietary VHH discovery and
engineering platforms. Our modular approach enables the design of bispecific, trispecific, and antibody-drug
conjugate candidates that target multiple cancer pathways with precision.
A Platform Built for Precision and Flexibility
Our VHH-based platform combines diverse antibody libraries, advanced screening, and modular engineering to support rapid discovery of developable candidates for complex oncology targets.
Focused on Hard-to-Treat Solid Tumors
We focus on solid tumors where therapeutic resistance, pathway redundancy, and limited treatment options remain major challenges. By integrating multispecific targeting with ADC design, we aim to create differentiated therapeutic candidates with the potential for improved antitumor activity.
